Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    15 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T01:15:39.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.3; the v3.4.2 tag was removed.
    Difference
    0.0%
    Check dated 2026-03-11T19:57:37.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Added Overall Survival (OS) as an endpoint with follow-up up to 3 years and introduced multiple immune cell biomarkers (CD56, CD19, CD14, CD8, CD4, CD3, CD45) at various treatment-cycle timepoints. Removed prior CD8+ and CD3+ cell change endpoints measured at baseline and early post-treatment.
    Difference
    8%
    Check dated 2026-02-18T07:22:37.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-status notice and the prior Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T05:37:57.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Added a site-wide notice about potential data not being up to date due to a lapse in government funding and updated the site revision from 3.4.0 to 3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T05:34:04.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The page now includes a glossary toggle and updated metadata labels, including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. The previous labels such as 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed or renamed.
    Difference
    0.2%
    Check dated 2026-01-28T03:11:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.